Author

Y. Kapelyukh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 1 Approach:mechanistic / dynamical model· 1 Approach:statistical model· 1

Frequent Co-Authors

C. R. Wolf· 2 shared M. A. J. Chaplain· 2 shared A. De Carli· 1 shared A. McLaren· 1 shared C. J. Henderson· 1 shared J. Kursawe· 1 shared S. Hamis· 1 shared S. J. HAMIS· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. R. Wolf

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies

A. De Carli, Y. Kapelyukh, J. Kursawe, M. A. J. Chaplain, C. R. Wolf, S. J. HAMIS

This paper develops a mathematical model of BRAFV600E-MEK-ERK signaling dynamics to simulate responses to vertical inhibition treatment strategies and identify effective combinations.

bioRxiv · Dec 12, 2023Cancer Biology

Quantifying ERK-activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling

S. Hamis, Y. Kapelyukh, A. McLaren, C. J. Henderson, C. R. Wolf, M. A. J. Chaplain

This study develops a mathematical model to quantify how dabrafenib and trametinib inhibit ERK-activity in BRAFV600E-mutant melanoma cells and identify mechanisms of drug resistance.

bioRxiv · Apr 20, 2021Cancer Biology